Thanks chazzledazzle. Jay certainly has announced many "tantalizing" nuggets this year that are coming. Exciting stuff.

Combo trials are coming but I like that it has been indicated that the upcoming preclinical MASH combo trial including Rezdiffra also has Leronlimab as a monotherapy arm of the study.

Prior to the FDA giving a full approval to Leronlimab as a stand-alone treatment in anything, I think it would be especially unwise for any combo studies to not also have leronlimab in monotherapy arms of those same combo studies. The head to head comparisons will show Leronlimabs' true value and possibly give Cytodyn significant financial leverage. It may also prevent administering superfluous additional drugs to patients when applicable.

I think the race is on for Cytodyn to show how well it works in phase 2 clinical trials over as many indications it can in order to show its true value in the data as a platform drug. When that realization resonates with larger pools of investors, things get wild.